The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species

Clinical Infectious Diseases

Volumn 43, Issue SUPPL. 2, 2006, Pages

  Paterson, David L ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CEFEPIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COLISTIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN B; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN; TIGECYCLINE; TOBRAMYCIN;

ACINETOBACTER; BACTERIAL INFECTION; BACTERIUM ISOLATION; CONFERENCE PAPER; HIGH RISK PATIENT; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; INFECTION RESISTANCE; INTENSIVE CARE UNIT; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MOLECULAR EPIDEMIOLOGY; MULTIDRUG RESISTANCE; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STRAIN DIFFERENCE; VENTILATOR ASSOCIATED PNEUMONIA; COMMUNICABLE DISEASE; CROSS INFECTION; DRUG EFFECT; GENETICS; GRAM NEGATIVE INFECTION; HEALTH SURVEY; MICROBIOLOGY; PRACTICE GUIDELINE; REVIEW;

ACINETOBACTER; ACINETOBACTER INFECTIONS; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; POPULATION SURVEILLANCE; PRACTICE GUIDELINES; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 33747595241     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/504476     Document Type: Conference Paper

References (55)

1. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171:388-416.
2. Ortega B, Groeneveld AB, Schultsz C. Endemic multidrug-resistant Pseudomonas aeruginosa in critically ill patients. Infect Control Hosp Epidemiol 2004; 25:825-31.
3. Defez C, Fabbro-Peray P, Bouziges N, et al. Risk factors for multidrug-resistant Pseudomonas aeruginosa nosocomial infection. J Hosp Infect 2004; 57:209-16.
4. Wisplinghoff H, Edmond MB, Pfaller MA, Jones RN, Wenzel RP, Seifert H. Nosocomial bloodstream infections caused by Acinetobacter species in United States hospitals: clinical features, molecular epidemiology, and antimicrobial susceptibility. Clin Infect Dis 2000; 31:690-7.
5. Nouer SA, Nucci M, de-Oliveira MP, Pellegrino FL, Moreira BM. Risk factors for acquisition of multidrug-resistant Pseudomonas aeruginosa producing SPM metallo-β-lactamase. Antimicrob Agents Chemother 2005; 49:3663-7.
6. Hilf M, Yu VL, Sharp J, Zuravleff JJ, Korvick JA, Muder RR. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am J Med 1989; 87:540-6.
7. Kiska DL, Gilligan PH. Pseudomonas. In: Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Yolken RH, eds. Manual of clinical microbiology. 8th ed. Vol. 1. Washington, DC: American Society for Microbiology Press, 2003:719-28.
8. Arancibia F, Bauer TT, Ewig S, et al. Community-acquired pneumonia due to gram-negative bacteria and Pseudomonas aeruginosa: incidence, risk, and prognosis. Arch Intern Med 2002; 162:1849-58.
9. Hatchette TF, Gupta R, Marrie TJ. Pseudomonas aeruginosa community-acquired pneumonia in previously healthy adults: case report and review of the literature. Clin Infect Dis 2000; 31:1349-56.
10. Mandell LA, Bartlett JG, Dowell SF, File TM Jr, Musher DM, Whitney C. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003; 37:1405-33.
11. Getchell-White SI, Donowitz LG, Groschel DH. The inanimate environment of an intensive care unit as a potential source of nosocomial bacteria: evidence for long survival of Acinetobacter calcoaceticus. Infect Control Hosp Epidemiol 1989; 10:402-7.
12. Seifert H, Dijkshoorn L, Gerner-Smidt P, Pelzer N, Tjernberg I, Vaneechoutte M. Distribution of Acinetobacter species on human skin: comparison of phenotypic and genotypic identification methods. J Clin Microbiol 1997; 35:2819-25.
13. Schreckenberger PC, Daneshvar MI, Weyant RS, Hollis DG. Acinetobacter, Achromobacter, Chryseobacterium, Moraxella, and other non-fermentative gram-negative rods. In: Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Yolken RH, eds. Manual of clinical microbiology. 8th ed. Vol. 1. Washington, DC: American Society for Microbiology Press, 2003:749-79.
14. Anstey NM, Currie BJ, Withnall KM. Community-acquired Acinetobacter pneumonia in the Northern Territory of Australia. Clin Infect Dis 1992; 14:83-91.
15. Gottlieb T, Barnes DJ. Community- acquired Acinetobacter pneumonia. Aust NZ J Med 1989; 19:259-60.
16. Bick JA, Semel JD. Fulminant community-acquired Acinetobacter pneumonia in a healthy woman. Clin Infect Dis 1993; 17:820-1.
17. Anstey NM, Currie BJ, Hassell M, Palmer D, Dwyer B, Seifert H. Community-acquired bacteremic Acinetobacter pneumonia in tropical Australia is caused by diverse strains of Acinetobacter baumannii, with carriage in the throat in at-risk groups. J Clin Microbiol 2002; 40:685-6.
18. Chen MZ, Hsueh PR, Lee LN, Yu CJ, Yang PC, Luh KT. Severe community-acquired pneumonia due to Acinetobacter baumannii. Chest 2001; 120:1072-7.
19. Morrison AJ Jr, Wenzel RP. Epidemiology of infections due to Pseudomonas aeruginosa. Rev Infect Dis 1984; 6(Suppl 3):S627-42.
20. Cross DF, Benchimol A, Dimond EG. The faucet aerator-a source of Pseudomonas infection. N Engl J Med 1966; 274:1430-1.
21. Teres D, Schweers P, Bushnell LS, Hedley-Whyte J, Feingold DS. Sources of Pseudomonas aeruginosa infection in a respiratory-surgical intensive-therapy unit. Lancet 1973; 1:415-7.
22. Srinivasan A, Wolfenden LL, Song X, et al. An outbreak of Pseudomonas aeruginosa infections associated with flexible bronchoscopes. N Engl J Med 2003; 348:221-7.
23. Moolenaar RL, Crutcher JM, San Joaquin VH, et al. A prolonged outbreak of Pseudomonas aeruginosa in a neonatal intensive care unit: did staff fingernails play a role in disease transmission? Infect Control Hosp Epidemiol 2000; 21:80-5.
24. Villegas MV, Hartstein AI. Acinetobacter outbreaks, 1977-2000. Infect Control Hosp Epidemiol 2003; 24:284-95.
25. Maragakis LL, Cosgrove SE, Song X, et al. An outbreak of multidrug-resistant Acinetobacter baumannii associated with pulsatile lavage wound treatment. JAMA 2004; 292:3006-11.
26. Denton M, Wilcox MH, Parnell P, et al. Role of environmental cleaning in controlling an outbreak of Acinetobacter baumannii on a neurosurgical intensive care unit. J Hosp Infect 2004; 56:106-10.
27. Jawad A, Seifert H, Snelling AM, Heritage J, Hawkey PM. Survival of Acinetobacter baumannii on dry surfaces: comparison of outbreak and sporadic isolates. J Clin Microbiol 1998; 36:1938-41.
28. Bureau-Chalot F, Drieux L, Pierrat-Solans C, Forte D, de Champs C, Bajolet O. Blood pressure cuffs as potential reservoirs of extended-spectrum β-lactamase VEB-1-producing isolates of Acinetobacter baumannii. J Hosp Infect 2004; 58:91-2.
29. Fink MP, Snydman DR, Niederman MS, et al. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group. Antimicrob Agents Chemother 1994; 38:547-57.
30. El Amari EB, Chamot E, Auckenthaler R, Pechere JC, Van Delden C. Influence of previous exposure to antibiotic therapy on the susceptibility pattern of Pseudomonas aeruginosa bacteremic isolates. Clin Infect Dis 2001; 33:1859-64.
31. Milatovic D, Braveny I. Development of resistance during antibiotic therapy. Eur J Clin Microbiol 1987; 6:234-44.
32. Wade JC. Antibiotic therapy for the febrile granulocytopenic cancer patient: combination therapy vs. monotherapy. Rev Infect Dis 1989; 11(Suppl 7):S1572-81.
33. Fish DN, Piscitelli SC, Danziger LH. Development of resistance during antimicrobial therapy: a review of antibiotic classes and patient characteristics in 173 studies. Pharmacotherapy 1995; 15:279-91.
34. Thomas JK, Forrest A, Bhavnani SM, et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 1998; 42:521-7.
35. Drusano GL, Sorgel F, Quinn J, Mason B, Melnick D. Impact of pharmacodynamic dosing of meropenem on emergence of resistance during treatment of ventilator-associated pneumonia: a prospective clinical trial [abstract K-127]. In: Program and abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington, DC). Washington, DC: American Society for Microbiology, 2005:298.
36. Paul M, Silbiger I, Grozinsky S, Soares-Weiser K, Leibovici L. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev 2006; 1:CD003344.
37. Bratu S, Quale J, Cebular S, Heddurshetti R, Landman D. Multidrug-resistant Pseudomonas aeruginosa in Brooklyn, New York: molecular epidemiology and in vitro activity of polymyxin B. Eur J Clin Microbiol Infect Dis 2005; 24:196-201.
38. Paramythiotou E, Lucet JC, Timsit JF, et al. Acquisition of multidrug-resistant Pseudomonas aeruginosa in patients in intensive care units: role of antibiotics with antipseudomonal activity. Clin Infect Dis 2004; 38:670-7.
39. Paterson DL, Panarello G, Dolce L, et al. Successful control of an outbreak of infection due to panresistant Pseudomonas aeruginosa producing a VIM-type carbapenemase [abstract 1181]. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 2000:418.
40. Tacconelli E, Tumbarello M, Bertagnolio S, et al. Multidrug-resistant Pseudomonas aeruginosa bloodstream infections: analysis of trends in prevalence and epidemiology. Emerg Infect Dis 2002; 8:220-1.
41. Maslow JN, Glaze T, Adams P, Lataillade M. Concurrent outbreak of multidrug-resistant and susceptible subclones of Acinetobacter baumannii affecting different wards of a single hospital. Infect Control Hosp Epidemiol 2005; 26:69-75.
42. Husni RN, Goldstein LS, Arroliga AC, et al. Risk factors for an outbreak of multi-drug-resistant Acinetobacter nosocomial pneumonia among intubated patients. Chest 1999; 115:1378-82.
43. Scerpella EG, Wanger AR, Armitige L, Anderlini P, Ericsson CD. Nosocomial outbreak caused by a multiresistant clone of Acinetobacter baumannii: results of the case-control and molecular epidemiologic investigations. Infect Control Hosp Epidemiol 1995; 16:92-7.
44. Carbonne A, Naas T, Blanckaert K, et al. Investigation of a nosocomial outbreak of extended-spectrum β-lactamase VEB-1-producing isolates of Acinetobacter baumannii in a hospital setting. J Hosp Infect 2005; 60:14-8.
45. Landman D, Quale JM, Mayorga D, et al. Citywide clonal outbreak of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY: the preantibiotic era has returned. Arch Intern Med 2002; 162:1515-20.
46. del Mar Tomas M, Cartelle M, Pertega S, et al. Hospital outbreak caused by a carbapenem-resistant strain of Acinetobacter baumannii: patient prognosis and risk-factors for colonisation and infection. Clin Microbiol Infect 2005; 11:540-6.
47. Lee SO, Kim NJ, Choi SH, et al. Risk factors for acquisition of imipenem-resistant Acinetobacter baumannii: a case-control study. Antimicrob Agents Chemother 2004; 48:224-8.
48. Corbella X, Montero A, Pujol M, et al. Emergence and rapid spread of carbapenem resistance during a large and sustained hospital outbreak of multiresistant Acinetobacter baumannii. J Clin Microbiol 2000; 38: 4086-95.
49. Villers D, Espaze E, Coste-Burel M, et al. Nosocomial Acinetobacter baumannii infections: microbiological and clinical epidemiology. Ann Intern Med 1998; 129:182-9.
50. Harris A, Torres-Viera C, Venkataraman L, DeGirolami P, Samore M, Carmeli Y. Epidemiology and clinical outcomes of patients with multiresistant Pseudomonas aeruginosa. Clin Infect Dis 1999; 28:1128-33.
51. Crespo MP, Woodford N, Sinclair A, et al. Outbreak of carbapenem-resistant Pseudomonas aeruginosa producing VIM-8, a novel metalloβ-lactamase, in a tertiary care center in Cali, Colombia. J Clin Microbiol 2004; 42:5094-101.
52. Tsakris A, Pournaras S, Woodford N, et al. Outbreak of infections caused by Pseudomonas aeruginosa producing VIM-1 carbapenemase in Greece. J Clin Microbiol 2000; 38:1290-2.
53. Deplano A, Denis O, Poirel L, et al. Molecular characterization of an epidemic clone of panantibiotic-resistant Pseudomonas aeruginosa. J Clin Microbiol 2005; 43:1198-204.
54. Quale J, Bratu S, Landman D, Heddurshetti R. Molecular epidemiology and mechanisms of carbapenem resistance in Acinetobacter baumannii endemic in New York City. Clin Infect Dis 2003; 37:214-20.
55. National Nosocomial Infections Surveillance. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004; 32:470-85.